Following a dramatic rise in breast cancer among friends and family, including his mother-in-law, Mr. Shah founded UE LifeSciences, Inc. in 2009. In founding UELS, Mr. Shah had a vision to change the way women detect breast cancer around the world.
Before NoTouch BreastScan, Mr. Shah's efforts led to innovative, non-invasive products like IQ, Zoe, and InfraScanner. With experience in the commercialization of medical device technology, clinical validation, product development, regulatory pathway, market entry, and international sales, Mr. Shah helped bring concepts-to-clinic quickly and within budget.
Under Mr. Shah's leadership, UELS has been successful in conducting three international clinical studies, gaining FDA/CE clearance of NoTouch BreastScan, and facilitating international sales growth prior to receiving FDA clearance. In 2010, Mr. Shah executed a worldwide exclusive license with Drexel University for its Piezoelectric Sensor technology. In August 2012, UELS was awarded $878,244 in grant funding from the Pennsylvania Department of Health under an application authored by Mr. Shah.
Mr. Shah is the recipient of the 2001 Business Plan Competition Award, presented by the Laurence A. Baiada Center for Entrepreneurship at Drexel University. He currently serves as an Entrepreneur-in-residence at Drexel's School of Biomedical Engineering. Mr. Shah has a B.S. in Computer and Electronics Engineering from Drexel University.
Mr. Campisi is a scientist and professor who has dedicated his professional career to early detection of breast cancer. After the revelation that his family was a carrier of the BRCA genetic mutation, Mr. Campisi began focusing on non-invasive technologies that would be suitable for young women to detect the earliest signs of the disease. His efforts have spanned the entire lifecycle of such technologies: from idea conception and realization, to commercialization and regulatory clearance.
Mr. Campisi co-founded Infrared Sciences in 1999 and served as VP of Computer Systems since the company's formation. At Infrared Sciences, he designed the first fully automated digital infrared breast imaging system. This system was used in one of the most influential clinical trials, validating the effectiveness of digital infrared imaging. In addition to designing the system, Mr. Campisi facilitated FDA clearance and commercialized the device around the world.
In 2009, Mr. Campisi Co-founded UE LifeSciences (UELS). At UELS, Mr. Campisi serves as Chief Technology Officer and oversees all technological activity. He developed NoTouch BreastScan, the world's first dual-digital infrared breast imaging system for breast cancer detection. NoTouch BreastScan has spanned the globe and has made a significant impact both in the United States and abroad. In 2012, NoTouch BreastScan received FDA clearance for commercialization in the US.
Mr. Campisi is an industry faculty member at Polytechnic Institute of NYU, and holds degrees in both Electrical Engineering and Computer Engineering. His research remains focused on globally adoptable techniques for early breast cancer detection.